ALMR.US Alamar Biosciences, Inc. Common Stock
- Market cap
- USD 2.14B
- P/E
- -
- P/B
- 7.28x
- ROE
- -21.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALMR.US undervalued?
Graham numberThe Graham number of Alamar Biosciences, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alamar Biosciences, Inc. Common Stock fundamental analysis
No fundamental analysis for Alamar Biosciences, Inc. Common Stock yet.
Alamar Biosciences, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alamar Biosciences, Inc. Common Stock
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the conti…
Full company profileAlamar Biosciences, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alamar Biosciences, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 25.1M | 74.2M | 119M |
| Gross Profit | 8.61M | 41.7M | 70.4M |
| Operating Income | -49.6M | -31.3M | -54.7M |
| EBITDA | -41.8M | -24.9M | -59.3M |
| Net Income | -47.1M | -29.8M | -63.8M |
| EPS | -0.71 | -0.45 | -0.92 |
| Balance Sheet | |||
| Total Assets | 150M | 140M | 378M |
| Total Liabilities | 283M | 299M | 74.3M |
| Shareholders' Equity | -133M | -159M | 304M |
| Cash & Short-term Investments | 79.4M | 30.0M | 227M |
| Total Debt | 33.1M | 41.5M | 42.4M |
| Cash Flow | |||
| Operating Cash Flow | -55.2M | -53.6M | -61.9M |
| Capital Expenditure | 3.39M | 6.38M | 6.27M |
| Free Cash Flow | -58.6M | -60.0M | -68.1M |
| Ratios | |||
| ROE | - | - | -21.0% |
| ROA | -31.5% | -21.3% | -16.9% |
| Net Profit Margin | -187.2% | -40.2% | -53.8% |
| Debt to Equity | - | - | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alamar Biosciences, Inc. Common Stock dividends
Alamar Biosciences, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Alamar Biosciences, Inc. Common Stock
- Insiders 22.29%
- Institutions 58.91%
- Public & others 18.81%
- Shares outstanding 69.5M
- Free float 42.0M
Top funds holding ALMR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Genomic Revolution ETF | 1.17M | 1.68% | +0.58% | Oct 2026 |
| ARK Venture D | 668K | 0.96% | +25.56% | Jul 2026 |
| T. Rowe Price Small-Cap Stock | 623K | 0.90% | 0.00% | Sep 2026 |
| AB Small Cap Growth A | 587K | 0.85% | -2.26% | Sep 2026 |
| Principal SmallCap Growth I Instl | 386K | 0.56% | +1.33% | Sep 2026 |
| Columbia Small Cap Growth Inst | 368K | 0.53% | -22.15% | Sep 2026 |
| T. Rowe Price Instl Small-Cap Stock | 341K | 0.49% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 336K | 0.48% | 0.00% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 320K | 0.46% | 0.00% | Sep 2026 |
| Emerald Growth A | 308K | 0.44% | +9.78% | Sep 2026 |
| Fidelity Select Health Care | 300K | 0.43% | 0.00% | Aug 2026 |
| Artisan Small Cap Investor | 295K | 0.42% | +52.49% | Sep 2026 |
| Fidelity Select Medical Tech and Devcs | 280K | 0.40% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 167K | 0.24% | +117.54% | Sep 2026 |
| Fidelity Advisor Health Care I | 160K | 0.23% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 87.0K | 0.13% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 78.6K | 0.11% | +2.96% | Sep 2026 |
| AB Small Cap Core Z | 78.0K | 0.11% | 0.00% | Sep 2026 |
| Lord Abbett Micro Cap Growth I | 75.4K | 0.11% | +11.24% | Aug 2026 |
| ARK Genomic Revolution ETF A USD Acc | 72.2K | 0.10% | 0.00% | Oct 2026 |
Top institutions holding ALMR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sands Capital Ventures, LLC | 4.23M | 6.10% | 0.00% | Jun 2026 |
| Samsara BioCapital, LLC | 2.48M | 3.57% | 0.00% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 2.20M | 3.17% | 0.00% | Jun 2026 |
| ARK Investment Management LLC | 1.37M | 1.98% | 0.00% | Jun 2026 |
| BRAIDWELL LP | 1.08M | 1.56% | 0.00% | Jun 2026 |
| AllianceBernstein L.P. | 1.00M | 1.45% | 0.00% | Jun 2026 |
| Hillhouse Capital Advisors, Ltd. | 956K | 1.38% | 0.00% | Jun 2026 |
| BlackRock Inc | 911K | 1.31% | 0.00% | Jun 2026 |
| Millennium Management LLC | 866K | 1.25% | 0.00% | Jun 2026 |
| FMR Inc | 829K | 1.20% | 0.00% | Jun 2026 |
| PURA VIDA INVESTMENTS, LLC | 756K | 1.09% | 0.00% | Jun 2026 |
| Emerald Advisers, LLC | 647K | 0.93% | 0.00% | Jun 2026 |
| Artisan Partners Limited Partnership | 614K | 0.88% | 0.00% | Jun 2026 |
| Deerfield Management Co | 600K | 0.86% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 463K | 0.67% | 0.00% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 463K | 0.67% | 0.00% | Jun 2026 |
| Wellington Management Company LLP | 458K | 0.66% | 0.00% | Jun 2026 |
| Emerald Mutual Fund Advisers Trust | 422K | 0.61% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 419K | 0.60% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 330K | 0.48% | 0.00% | Jun 2026 |
Alamar Biosciences, Inc. Common Stock company profile
- Company name
- Alamar Biosciences, Inc. Common Stock
- Ticker
- ALMR.US
- Exchange
- USA Stocks
- Listed since
- Apr 17, 2026
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 308
- Fiscal year end
- December
- Address
- 47071 Bayside Parkway, Fremont, CA, United States, 94538
- Phone
- (510) 626-9888
- Website
- alamarbio.com
About Alamar Biosciences, Inc. Common Stock
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. Alamar Biosciences, Inc. has a strategic scientific collaboration with GSK plc to use its NULISA platform to analyze circulating protein signatures for precision medicine. The company was incorporated in 2018 and is based in Fremont, California.
Alamar Biosciences, Inc. Common Stock management
10- Dr. Yuling Luo Ph.D.Co-Founder, Chairman & CEO · born 1964
- Dr. Shiping Chen Ph.D.Co-Founder, COO & Director · born 1963
- Mr. Justin J. McAnearChief Financial Officer · born 1976
- Mr. Timothy Ogden White J.D.President · born 1968
- Ms. Yiyuan Yin Ph.D.Co-Founder, VP of Technology & Acting Secretary
- Dr. Xiao-Jun Ma Ph.D.Chief Technology Officer
- Dr. Stephen A. Williams M.D., Ph.D.Chief Scientific Officer · born 1960
- Ms. Carrie MendivilVice President of Investor Relations & Corporate Communications
- Mr. John L. Brottem J.D.General Counsel · born 1974
- Mr. Alex Forrest-HaySenior Vice President of Sales